These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12503820)

  • 21. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.
    Dine T; Cazin JC; Gressier B; Luyckx M; Brunet C; Cazin M; Goudaliez F; Mallevais ML; Toraub I
    Pharm Weekbl Sci; 1992 Dec; 14(6):365-9. PubMed ID: 1475177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer.
    Danson S; Ferry D; Alakhov V; Margison J; Kerr D; Jowle D; Brampton M; Halbert G; Ranson M
    Br J Cancer; 2004 Jun; 90(11):2085-91. PubMed ID: 15150584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
    Ali-el-Dein B; el-Baz M; Aly AN; Shamaa S; Ashamallah A
    J Urol; 1997 Jul; 158(1):68-73; discussion 73-4. PubMed ID: 9186325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of acute hepatic failure on epirubicin pharmacokinetics after intrahepatic arterial injection in rats.
    Nagata M; Matsuo Y; Hidaka M; Kawano Y; Okumura M; Tokunaga J; Takamura N; Arimori K
    Biol Pharm Bull; 2008 Mar; 31(3):493-6. PubMed ID: 18310916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A pharmacokinetic study of intra-arterial chemotherapy for prophylactic treatment of liver metastasis after hepatectomy for liver cancer].
    Umekita N; Awane Y; Maeshiro T; Miyamoto S; Yamada F; Matsumine T
    Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1544-6. PubMed ID: 1530304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients].
    Escudero-Ortiz V; Ramón-López A; Duart MA; Pérez-Ruixo JJ; Valenzuela B
    Farm Hosp; 2012; 36(4):282-91. PubMed ID: 22129650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.
    Venturini M; Lunardi G; Del Mastro L; Vannozzi MO; Tolino G; Numico G; Viale M; Pastrone I; Angiolini C; Bertelli G; Straneo M; Rosso R; Esposito M
    J Clin Oncol; 2000 May; 18(10):2116-25. PubMed ID: 10811677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An interim analysis of phase I clinical trial of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer.
    Matsumura Y
    Adv Exp Med Biol; 2003; 519():179-93. PubMed ID: 12675215
    [No Abstract]   [Full Text] [Related]  

  • 29. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors.
    Lübbe AS; Bergemann C; Riess H; Schriever F; Reichardt P; Possinger K; Matthias M; Dörken B; Herrmann F; Gürtler R; Hohenberger P; Haas N; Sohr R; Sander B; Lemke AJ; Ohlendorf D; Huhnt W; Huhn D
    Cancer Res; 1996 Oct; 56(20):4686-93. PubMed ID: 8840985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
    Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
    Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
    Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
    Ralph LD; Thomson AH; Dobbs NA; Twelves C
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
    Mita MM; Natale RB; Wolin EM; Laabs B; Dinh H; Wieland S; Levitt DJ; Mita AC
    Invest New Drugs; 2015 Apr; 33(2):341-8. PubMed ID: 25388939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
    Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
    Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres.
    Sottani C; Poggi G; Quaretti P; Regazzi M; Montagna B; Quaquarini E; Imbriani M; Leoni E; Di Cesare P; Riccardi A; Bernardo G; Minoia C
    Anticancer Res; 2012 May; 32(5):1769-74. PubMed ID: 22593459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue distribution of epirubicin after severe extravasation in humans.
    Nedomansky J; Haslik W; Pluschnig U; Kornauth C; Deutschmann C; Hacker S; Steger GG; Bartsch R; Mader RM
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):203-209. PubMed ID: 33907881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Images in clinical medicine. Extravasation of epirubicin.
    Vano-Galvan S; Jaen P
    N Engl J Med; 2009 May; 360(20):2117. PubMed ID: 19439746
    [No Abstract]   [Full Text] [Related]  

  • 39. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx/Doxil in patients with hematological tumors.
    Richly H; Grubert M; Scheulen ME; Hilger RA
    Int J Clin Pharmacol Ther; 2009 Jan; 47(1):55-7. PubMed ID: 19203539
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.